Skip to main content
Top
Published in: Rheumatology International 7/2020

01-07-2020 | Uveitis | Observational Research

Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study

Authors: Nuray Aktay Ayaz, Şerife Gül Karadağ, Rahime Koç, Fatma Gül Demirkan, Figen Çakmak, Hafize Emine Sönmez

Published in: Rheumatology International | Issue 7/2020

Login to get access

Abstract

Introduction

Juvenile idiopathic arthritis (JIA) is a heterogeneous group of idiopathic inflammatory arthritis affecting children younger than 16 years of age. Tocilizumab (TCZ) is a humanized anti-interleukin 6 (IL-6) receptor antibody that was approved for systemic and polyarticular JIA patients. However, the studies regarding patients’ satisfaction while receiving TCZ therapy is scarce. Herein, we aimed to evaluate the effect of subcutaneous (SC) TCZ administration on patient satisfaction and disease control of JIA patients.

Methods

All JIA patients receiving TCZ were included in the study. Clinical features, laboratory findings and JADAS71 scores were recorded at baseline and every 3 months during follow-up. Nine of the patients on intravenous (IV) TCZ treatment were switched to SC form. All patients receiving TCZ-SC were questioned by a clinical nurse specialist (CNS) to assess patient satisfaction.

Results

A total of 39 patients receiving TCZ were included in the study. Among them, treatment of nine patients (five female, four male) was switched to SC form with a median of 11.5 (8–69) months after initiation of TCZ. Patients were stable both clinically and in laboratory means at the 3rd month of TCZ-SC treatment. There was no deterioration in terms of active joint counts, physician’s VAS, patient’s VAS and JADAS71. According to patient satisfaction questionnaire, eight of the patients felt satisfied with SC administrations in terms of life quality, school success and reduced school absenteeism. However, one patient did not agree that the SC form is as effective as IV form and wanted to continue with IV form.

Conclusion

TCZ is an effective treatment option in JIA and switching from IV to SC route when necessary is found to be an effective and acceptable alternative by the patients as well.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ringold S, Weiss PF, Beukelman T et al (2013) 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 65:2499–2512CrossRef Ringold S, Weiss PF, Beukelman T et al (2013) 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 65:2499–2512CrossRef
2.
go back to reference Beukelman T, Patkar NM, Saag KG et al (2011) 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 63:465–482CrossRef Beukelman T, Patkar NM, Saag KG et al (2011) 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 63:465–482CrossRef
3.
go back to reference Ringold S, Weiss PF, Colbert RA et al (2014) Childhood arthritis and rheumatology research alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 66:1063–1072CrossRef Ringold S, Weiss PF, Colbert RA et al (2014) Childhood arthritis and rheumatology research alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 66:1063–1072CrossRef
4.
go back to reference Mallalieu NL, Wimalasundera S, Hsu JC et al (2019) Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial. Pediatr Rheumatol Online J 17:57CrossRef Mallalieu NL, Wimalasundera S, Hsu JC et al (2019) Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial. Pediatr Rheumatol Online J 17:57CrossRef
5.
go back to reference Ringold S, Angeles-Han ST, Beukelman T et al (2019) 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken) 71:717–734CrossRef Ringold S, Angeles-Han ST, Beukelman T et al (2019) 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken) 71:717–734CrossRef
6.
go back to reference Ogata A, Kato Y, Higa S, Maeda K (2019) Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis. Expert Opin Drug Deliv 16:639–648CrossRef Ogata A, Kato Y, Higa S, Maeda K (2019) Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis. Expert Opin Drug Deliv 16:639–648CrossRef
7.
go back to reference Petty RE, Southwood TR, Manners P et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390–392PubMed Petty RE, Southwood TR, Manners P et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390–392PubMed
8.
go back to reference Consolaro A, Ravelli A (2016) Defining criteria for disease activity states in juvenile idiopathic arthritis. Rheumatology (Oxford) 55:595–596CrossRef Consolaro A, Ravelli A (2016) Defining criteria for disease activity states in juvenile idiopathic arthritis. Rheumatology (Oxford) 55:595–596CrossRef
9.
go back to reference McErlane F, Beresford MW, Baildam EM et al (2013) Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis 72:1983–1988CrossRef McErlane F, Beresford MW, Baildam EM et al (2013) Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis 72:1983–1988CrossRef
10.
go back to reference Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, Malattia C, Viola S, Martini A, Ravelli A, Paediatric Rheumatology International Trials O (2009) Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 61:658–666CrossRef Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, Malattia C, Viola S, Martini A, Ravelli A, Paediatric Rheumatology International Trials O (2009) Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 61:658–666CrossRef
11.
go back to reference Dashiell-Aje E, Harding G, Pascoe K, DeVries J, Berry P, Ramachandran S (2018) Patient evaluation of satisfaction and outcomes with an autoinjector for self-administration of subcutaneous belimumab in patients with systemic lupus erythematosus. Patient 11:119–129CrossRef Dashiell-Aje E, Harding G, Pascoe K, DeVries J, Berry P, Ramachandran S (2018) Patient evaluation of satisfaction and outcomes with an autoinjector for self-administration of subcutaneous belimumab in patients with systemic lupus erythematosus. Patient 11:119–129CrossRef
12.
go back to reference De Benedetti F, Brunner HI, Ruperto N et al (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367:2385–2395CrossRef De Benedetti F, Brunner HI, Ruperto N et al (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367:2385–2395CrossRef
13.
go back to reference Brunner HI, Ruperto N, Zuber Z et al (2015) Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 74:1110–1117CrossRef Brunner HI, Ruperto N, Zuber Z et al (2015) Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 74:1110–1117CrossRef
14.
go back to reference Curtis JR, Schabert VF, Harrison DJ, Yeaw J, Korn JR, Quach C, Yun H, Joseph GJ, Collier DH (2014) Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims. Clin Ther 36:996–1004CrossRef Curtis JR, Schabert VF, Harrison DJ, Yeaw J, Korn JR, Quach C, Yun H, Joseph GJ, Collier DH (2014) Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims. Clin Ther 36:996–1004CrossRef
15.
go back to reference Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR (2004) Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2:12CrossRef Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR (2004) Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2:12CrossRef
16.
go back to reference Desplats M, Pascart T, Jelin G, Norberciak L, Philippe P, Houvenagel E, Goeb V, Flipo RM (2017) Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study. Clin Rheumatol 36:1395–1400CrossRef Desplats M, Pascart T, Jelin G, Norberciak L, Philippe P, Houvenagel E, Goeb V, Flipo RM (2017) Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study. Clin Rheumatol 36:1395–1400CrossRef
17.
go back to reference Rush ET, DeHaai K, Kreikemeier RM, Lutz RE (2012) Evaluation and comparison of safety, convenience and cost of administering intravenous pamidronate infusions to children in the home and ambulatory care settings. J Pediatr Endocrinol Metab 25:493–497CrossRef Rush ET, DeHaai K, Kreikemeier RM, Lutz RE (2012) Evaluation and comparison of safety, convenience and cost of administering intravenous pamidronate infusions to children in the home and ambulatory care settings. J Pediatr Endocrinol Metab 25:493–497CrossRef
18.
go back to reference Lechanska-Helman J, Sobocinska A, Jerzynska J, Stelmach I (2020) The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with Primary Immunodeficiency Diseases on their parents/caregivers satisfaction. Pediatr Int 62:316–318CrossRef Lechanska-Helman J, Sobocinska A, Jerzynska J, Stelmach I (2020) The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with Primary Immunodeficiency Diseases on their parents/caregivers satisfaction. Pediatr Int 62:316–318CrossRef
19.
go back to reference Odinet JS, Day CE, Cruz JL, Heindel GA (2018) The biosimilar nocebo effect? A systematic review of double-blinded versus open-label studies. J Manag Care Spec Pharm 24:952–959PubMed Odinet JS, Day CE, Cruz JL, Heindel GA (2018) The biosimilar nocebo effect? A systematic review of double-blinded versus open-label studies. J Manag Care Spec Pharm 24:952–959PubMed
20.
go back to reference Huynh TK, Ostergaard A, Egsmose C, Madsen OR (2014) Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adher 8:93–99 Huynh TK, Ostergaard A, Egsmose C, Madsen OR (2014) Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adher 8:93–99
21.
go back to reference Sylwestrzak G, Liu J, Stephenson JJ, Ruggieri AP, DeVries A (2014) Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options. Am Health Drug Benefits 7:71–81PubMedPubMedCentral Sylwestrzak G, Liu J, Stephenson JJ, Ruggieri AP, DeVries A (2014) Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options. Am Health Drug Benefits 7:71–81PubMedPubMedCentral
22.
go back to reference Quesada-Masachs E, Caballero CM (2017) Subcutaneous tocilizumab may be less effective than intravenous tocilizumab in the treatment of juvenile idiopathic arthritis-associated uveitis. J Rheumatol 44:260–261CrossRef Quesada-Masachs E, Caballero CM (2017) Subcutaneous tocilizumab may be less effective than intravenous tocilizumab in the treatment of juvenile idiopathic arthritis-associated uveitis. J Rheumatol 44:260–261CrossRef
Metadata
Title
Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study
Authors
Nuray Aktay Ayaz
Şerife Gül Karadağ
Rahime Koç
Fatma Gül Demirkan
Figen Çakmak
Hafize Emine Sönmez
Publication date
01-07-2020
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 7/2020
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-020-04596-3

Other articles of this Issue 7/2020

Rheumatology International 7/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.